Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135261 | 0.90 | KMT2A (0.50) | OPRM1OPRD1LMNAHRH3KMT2A | |
| SCHEMBL6135365 | 0.88 | OPRM1 (0.49) | OPRM1OPRD1LMNAHRH3KMT2A | |
| SCHEMBL6135091 | 0.84 | ALDH1A1 (0.49) | LMNAHRH3ALDH1A1 | |
| SCHEMBL6135361 | 0.82 | HRH3 (0.50) | HRH3ALDH1A1 | |
| SCHEMBL5640035 | 0.81 | HRH3 (0.54) | HRH3CTSLCTSBCTSS | |
| SCHEMBL6134957 | 0.81 | CTSL (0.47) | OPRM1OPRD1LMNAHRH3KMT2A | |
| SCHEMBL6134964 | 0.81 | KDM4E (0.60) | LMNAHRH3KMT2AALDH1A1KDM4E | |
| SCHEMBL6134380 | 0.80 | HRH1 (0.49) | OPRM1OPRD1LMNAHRH3KMT2A | |
| SCHEMBL6135024 | 0.80 | CTSL (0.46) | OPRM1OPRD1LMNAHRH3KMT2A | |
| SCHEMBL6134554 | 0.79 | HRH3 (0.51) | HRH3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | OPRM1 4731/4885OPRD1 4329/4885LMNA 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.